Immunotherapy and anti-VEGF with or without local therapy for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a diagnosis of hepatocellular carcinoma (liver cancer).
- Your cancer should be at stage B or C (not early stage that can be removed by surgery).
- You must have at least one tumor that can be measured on scans.
- You should be in good overall health (ECOG score 0 or 1, meaning you can do daily activities without help).
- Your liver function must be Child-Pugh class A or B (fairly good liver function).
- You cannot have had local treatments (like chemoembolization, radiation, or alcohol injection) in the last 4 weeks.
- You cannot have an active autoimmune disease or a history of one.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial compares two ways to deliver chemotherapy into the liver—TACE (a targeted injection that blocks blood flow) and HAIC (a continuous infusion through a small tube)—along with an immunotherapy drug (PD-1 inhibitor) and a targeted therapy pill (lenvatinib). It's for people with liver cancer that cannot be removed by surgery.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.